NO970374L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO970374L
NO970374L NO970374A NO970374A NO970374L NO 970374 L NO970374 L NO 970374L NO 970374 A NO970374 A NO 970374A NO 970374 A NO970374 A NO 970374A NO 970374 L NO970374 L NO 970374L
Authority
NO
Norway
Prior art keywords
new connections
connections
new
Prior art date
Application number
NO970374A
Other languages
English (en)
Norwegian (no)
Other versions
NO970374D0 (no
Inventor
Michael Joseph Browne
Kay Elizabeth Murphy
Conrad Gerald Chapman
Helen Elizabeth Clinkenbeard
Peter Ronald Young
Allan Richard Shatzman
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9415379A external-priority patent/GB9415379D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Corp filed Critical Smithkline Beecham Plc
Publication of NO970374D0 publication Critical patent/NO970374D0/no
Publication of NO970374L publication Critical patent/NO970374L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO970374A 1994-07-29 1997-01-28 Nye forbindelser NO970374L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9415379A GB9415379D0 (en) 1994-07-29 1994-07-29 Novel compounds
US46829795A 1995-06-06 1995-06-06
PCT/EP1995/003036 WO1996004388A1 (en) 1994-07-29 1995-07-28 Novel compounds

Publications (2)

Publication Number Publication Date
NO970374D0 NO970374D0 (no) 1997-01-28
NO970374L true NO970374L (no) 1997-02-19

Family

ID=26305369

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970374A NO970374L (no) 1994-07-29 1997-01-28 Nye forbindelser

Country Status (13)

Country Link
EP (1) EP0770135A1 (zh)
JP (1) JPH10503371A (zh)
CN (1) CN1117155C (zh)
AU (1) AU3382595A (zh)
BR (1) BR9508469A (zh)
CA (1) CA2196200A1 (zh)
CZ (1) CZ25697A3 (zh)
HU (1) HUT76369A (zh)
MX (1) MX9700764A (zh)
NO (1) NO970374L (zh)
NZ (1) NZ292124A (zh)
PL (1) PL182665B1 (zh)
WO (1) WO1996004388A1 (zh)

Families Citing this family (203)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6664227B1 (en) 1996-03-01 2003-12-16 Genetics Institute, Llc Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
EP0812913A3 (en) * 1996-06-12 1999-08-04 Smithkline Beecham Corporation HR-1 receptor, a receptor of the cytokine receptors family
US5986059A (en) * 1996-06-14 1999-11-16 Bayer Corporation T-cell selective interleukin-4 agonists
US6335426B1 (en) 1996-06-14 2002-01-01 Bayer Corporation T-cell selective interleukin-4 agonists
US6028176A (en) 1996-07-19 2000-02-22 Bayer Corporation High-affinity interleukin-4 muteins
US6287801B1 (en) * 1996-07-22 2001-09-11 Smithkline Beecham Corporation Nucleic acids encoding the G-protein coupled receptor HNFDS78
CA2275183A1 (en) * 1996-12-20 1998-07-02 Amgen Inc. Ob fusion protein compositions and methods
US6100387A (en) * 1997-02-28 2000-08-08 Genetics Institute, Inc. Chimeric polypeptides containing chemokine domains
US6852508B1 (en) 1997-02-28 2005-02-08 Genetics Institute, Llc Chemokine with amino-terminal modifications
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
CA2323776C (en) 1998-03-19 2010-04-27 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP1161451A4 (en) 1999-02-26 2006-05-17 Human Genome Sciences Inc HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
PT2281843T (pt) 2000-06-16 2017-01-02 Human Genome Sciences Inc Anticorpos que se ligam imunoespecificamente a blys
EP2338512A1 (en) 2000-11-28 2011-06-29 MedImmune, LLC Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1683865A3 (en) 2001-02-02 2006-10-25 Eli Lilly & Company Mammalian proteins and in particular CD200
AU2002303098A1 (en) * 2001-02-22 2002-09-12 The Research Foundation Of State University Of New York Opiate receptors
GB0105360D0 (en) * 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
KR20030093316A (ko) 2001-04-13 2003-12-06 휴먼 게놈 사이언시즈, 인코포레이티드 혈관 내피 성장 인자 ２
AU2002309647C1 (en) 2001-05-25 2008-09-11 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
US20040091486A1 (en) 2002-05-10 2004-05-13 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7425620B2 (en) 2002-08-14 2008-09-16 Scott Koenig FcγRIIB-specific antibodies and methods of use thereof
AU2004207476A1 (en) * 2003-01-18 2004-08-12 Children's Hospital Medical Center Regulation of allergen induced gene
EP1444989A1 (en) 2003-02-07 2004-08-11 Giorgio Dr. Stassi Sensitizing cells for apoptosis by selectively blocking cytokines
DE602004027888D1 (de) 2003-02-20 2010-08-12 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihr
NZ542306A (en) 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
MXPA05013565A (es) * 2003-06-12 2006-03-09 Lilly Co Eli Proteinas de fusion analogas al glp-1.
WO2004110472A2 (en) * 2003-06-12 2004-12-23 Eli Lilly And Company Fusion proteins
EP2272566A3 (en) 2003-08-18 2013-01-02 MedImmune, LLC Humanisation of antibodies
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
EP1702069A2 (en) 2004-01-05 2006-09-20 EMD Lexigen Research Center Corp. Interleukin-12 targeted to oncofoetal fibronectin
US7973139B2 (en) 2004-03-26 2011-07-05 Human Genome Sciences, Inc. Antibodies against nogo receptor
WO2005113606A2 (en) * 2004-05-13 2005-12-01 Eli Lilly And Company Fgf-21 fusion proteins
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7700720B2 (en) 2004-09-21 2010-04-20 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US7635754B2 (en) * 2004-09-22 2009-12-22 Aerovance, Inc. Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
DE602005025525D1 (de) 2004-11-17 2011-02-03 Amgen Inc Vollständige humane monoklonale antikörper gegen il-13
CN101044162B (zh) * 2004-12-22 2010-10-27 伊莱利利公司 Glp-1类似物融合蛋白质制剂
EP1869192B1 (en) 2005-03-18 2016-01-20 MedImmune, LLC Framework-shuffling of antibodies
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
ES2561628T3 (es) 2005-05-06 2016-02-29 Zymogenetics, Inc. Anticuerpos monoclonales IL-31 y métodos de uso
AU2006261920A1 (en) 2005-06-23 2007-01-04 Medimmune, Llc Antibody formulations having optimized aggregation and fragmentation profiles
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
US8592149B2 (en) 2006-04-27 2013-11-26 Pikamab, Inc. Methods and compositions for antibody therapy
BRPI0713484A2 (pt) 2006-06-21 2012-11-06 Apogenix Gmbh expressão diferencial de citocina em cáncer humano
EP2029173B1 (en) 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
CA2661782C (en) 2006-08-28 2019-04-16 La Jolla Institute For Allergy And Immunology Antagonistic human light-specific human monoclonal antibodies
CA2660175C (en) 2006-09-01 2015-05-12 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
EP2407548A1 (en) 2006-10-16 2012-01-18 MedImmune, LLC Molecules with reduced half-lives, compositions and uses thereof
EP2609932B1 (en) 2006-12-01 2022-02-02 Seagen Inc. Variant target binding agents and uses thereof
US20110130544A1 (en) 2007-03-30 2011-06-02 Medimmune, Llc Antibodies with decreased deamidation profiles
SG194368A1 (en) 2007-05-04 2013-11-29 Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa Engineered rabbit antibody variable domains and uses thereof
SG10201503254TA (en) 2007-05-14 2015-06-29 Medimmune Llc Methods of reducing eosinophil levels
DK2796466T3 (en) * 2007-12-07 2018-02-05 Zymogenetics Inc HUMANIZED ANTIBODY MOLECULE SPECIFIC TO IL-31
US20110033378A1 (en) 2008-01-18 2011-02-10 Medlmmune, Llc. Cysteine Engineered Antibodies For Site-Specific Conjugation
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
KR101030978B1 (ko) * 2008-07-10 2011-04-28 (주) 에이프로젠 동물세포용 재조합 발현벡터
MX356218B (es) 2008-08-05 2018-05-18 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5.
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2010093993A2 (en) 2009-02-12 2010-08-19 Human Genome Sciences, Inc. Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
BRPI1016204A2 (pt) 2009-04-22 2016-04-19 Merck Patent Gmbh proteínas de fusão de anticorpos com sítios de ligação fcrn modificados
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
EP2445520A4 (en) 2009-06-22 2013-03-06 Medimmune Llc MANIPULATED FC REGIONS FOR LOCAL SPECIFIC CONJUGATION
KR101733255B1 (ko) 2009-07-20 2017-05-08 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 상승작용적 치료를 위한 항­ｃｔｌａ４ 항체와 다양한 치료 요법의 조합
EP2464657B1 (en) 2009-08-10 2015-04-01 MorphoSys AG Novel screening strategies for the identification of antibodies or fragments thereof which bind an antigen that has an enzymatic activity
EA023179B1 (ru) 2009-08-13 2016-05-31 Круселл Холланд Б.В. Антитела против респираторного синцитиального вируса (pcb) и способы их применения
EP2464661B1 (en) 2009-08-13 2018-01-17 The Johns Hopkins University Methods of modulating immune function with anti-b7-h7cr antibodies
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
JP2013527761A (ja) 2010-05-06 2013-07-04 ノバルティス アーゲー 治療的低密度リポタンパク質関連タンパク質６（ｌｒｐ６）多価抗体の組成物および使用方法
EP2590668A4 (en) 2010-07-09 2014-04-02 Biogen Idec Hemophilia Inc FACTOR IX POLYPEPTIDES AND METHOD OF USE THEREOF
KR101896124B1 (ko) 2010-07-09 2018-09-07 얀센 백신스 앤드 프리벤션 비.브이. 항-인간 호흡기 세포융합 바이러스(ｒｓｖ) 항체 및 사용 방법
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
JP6057896B2 (ja) 2010-08-20 2017-01-11 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
SG187965A1 (en) 2010-08-27 2013-04-30 Stem Centrx Inc Notum protein modulators and methods of use
CA2810016A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Novel modulators and methods of use
BR112013011811A2 (pt) 2010-11-05 2023-02-23 Zymeworks Inc Modelo de anticorpo heterodimérico estável com mutações no domínio fc
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
RU2016123839A (ru) 2010-12-08 2018-11-30 АббВай Стемсентркс ЭлЭлСи Новые модуляторы и способы их применения
EP3763740A1 (en) 2011-01-26 2021-01-13 Celldex Therapeutics, Inc. Anti-kit antibodies and uses thereof
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US20150044208A1 (en) 2011-09-23 2015-02-12 Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics
CN104053671A (zh) 2011-11-01 2014-09-17 生态学有限公司 治疗癌症的抗体和方法
AU2012332590B2 (en) 2011-11-01 2016-10-20 Bionomics, Inc. Anti-GPR49 antibodies
AU2012332593B2 (en) 2011-11-01 2016-11-17 Bionomics, Inc. Anti-GPR49 antibodies
AU2012332588B2 (en) 2011-11-01 2017-09-07 Bionomics, Inc. Methods of blocking cancer stem cell growth
EP3290442A1 (en) 2011-11-04 2018-03-07 Novartis AG Low density lipoprotein-related protein 6 (lrp6) half-life extender constructs
RS62689B1 (sr) 2011-11-04 2021-12-31 Zymeworks Inc Dizajn stabilnog heterodimernog antitela sa mutacijama u fc domenu
US9453073B2 (en) 2011-12-02 2016-09-27 Eli Lilly And Company Anti-glucagon antibodies and uses thereof
WO2013084148A2 (en) 2011-12-05 2013-06-13 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
JP6243345B2 (ja) 2011-12-05 2017-12-06 ノバルティス アーゲー 上皮細胞増殖因子受容体３（ｈｅｒ３）に対する抗体
CN106831985A (zh) 2011-12-21 2017-06-13 诺华股份有限公司 用于抗体靶定p因子的组合物和方法
WO2013093809A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6401060B2 (ja) 2012-02-24 2018-10-03 アッヴィ・ステムセントルクス・エル・エル・シー 抗ｓｅｚ６抗体及び使用方法
PE20190658A1 (es) 2012-02-24 2019-05-08 Abbvie Stemcentrx Llc Moduladores y metodos de empleo novedosos
CA2872540A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
KR102268351B1 (ko) 2012-07-25 2021-06-22 셀덱스 쎄라퓨틱스, 인크. 항-kit 항체 및 그의 용도
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
JP6306605B2 (ja) 2012-12-05 2018-04-04 ノバルティス アーゲー Ｅｐｏを標的とする抗体のための組成物および方法
EP2935589A1 (en) 2012-12-18 2015-10-28 Novartis AG Compositions and methods that utilize a peptide tag that binds to hyaluronan
JP6462591B2 (ja) 2013-02-22 2019-01-30 アッヴィ・ステムセントルクス・エル・エル・シー 新規抗体コンジュゲートおよびその使用
DK2970473T3 (da) 2013-03-14 2017-11-27 Bristol Myers Squibb Co Kombination af dr5-agonist og anti-pd-1-antagonist og fremgangsmåder til anvendelse heraf
CN105246916A (zh) 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
CN103265637B (zh) * 2013-06-04 2015-10-21 江苏众红生物工程创药研究院有限公司 一种重组猪白细胞介素4-Fc融合蛋白及其编码基因和表达方法
NZ714765A (en) 2013-06-06 2021-12-24 Pf Medicament Anti-c10orf54 antibodies and uses thereof
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
UY35620A (es) 2013-06-21 2015-01-30 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
HUE056325T2 (hu) 2013-08-26 2022-02-28 Biontech Res And Development Inc SIALYL-LEWIS A elleni humán antitesteket kódoló nukleinsavak
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
BR112016004242A8 (pt) 2013-08-28 2018-06-12 Stemcentrx Inc Métodos para conjugação sítio-específica de anticorpos e composições
MX2016005784A (es) 2013-11-04 2016-08-19 Pfizer Conjugados de anticuerpo anti-ligando efrina-a4-farmaco.
UA119863C2 (uk) 2014-01-24 2019-08-27 Нгм Біофармасьютікалс, Інк. Антитіло або його фрагмент, що зв'язується з бета-клото
US10308721B2 (en) 2014-02-21 2019-06-04 Abbvie Stemcentrx Llc Anti-DLL3 antibodies and drug conjugates for use in melanoma
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
MX2016012873A (es) 2014-04-04 2017-03-07 Bionomics Inc Anticuerpos humanizados que se unen al receptor 5 acoplado a proteina g que contiene repeticion rica en leucina (lgr5).
AU2015259465A1 (en) 2014-05-13 2016-11-17 Bioatla Llc Conditionally active biological proteins
EP3888690A3 (en) 2014-05-16 2021-10-20 MedImmune, LLC Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
AU2015271685B2 (en) 2014-06-04 2021-02-18 Biontech Research And Development, Inc. Human monoclonal antibodies to ganglioside GD2
WO2015198240A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
EP3161001A2 (en) 2014-06-25 2017-05-03 Novartis AG Antibodies specific for il-17a fused to hyaluronan binding peptide tags
WO2015198243A2 (en) 2014-06-25 2015-12-30 Novartis Ag Compositions and methods for long acting proteins
KR20240056627A (ko) 2014-08-07 2024-04-30 노파르티스 아게 안지오포이에틴-유사 4 항체 및 사용 방법
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
EP3189152A4 (en) 2014-09-03 2018-04-04 BioAtla LLC Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3333191B1 (en) 2014-12-11 2020-09-09 Pierre Fabre Medicament Anti-c10orf54 antibodies and uses thereof
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CN114504651A (zh) 2015-03-03 2022-05-17 科马布有限公司 抗体、用途和方法
WO2016193872A2 (en) 2015-06-05 2016-12-08 Novartis Ag Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
NZ740067A (en) 2015-09-09 2021-07-30 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
JP7064769B2 (ja) 2015-11-02 2022-05-11 バイオアトラ、エルエルシー 条件的活性型ポリペプチド
WO2017093947A1 (en) 2015-12-04 2017-06-08 Novartis Ag Antibody cytokine engrafted compositions and methods of use for immunoregulation
US20170198040A1 (en) 2015-12-18 2017-07-13 Novartis Ag ANTIBODIES TARGETING CD32b AND METHODS OF USE THEREOF
MA55746A (fr) 2016-01-21 2022-03-02 Novartis Ag Molécules multispécifiques ciblant cll-1
CN108697799A (zh) 2016-03-22 2018-10-23 生态学有限公司 抗lgr5单克隆抗体的施用
US11312766B2 (en) 2016-04-27 2022-04-26 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017216724A1 (en) 2016-06-15 2017-12-21 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (bmp6)
KR102602137B1 (ko) 2016-07-06 2023-11-13 브리스톨-마이어스 스큅 컴퍼니 Tim-4 길항제 및 pd-1 길항제의 조합물 및 사용 방법
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
EP3515943A4 (en) 2016-09-19 2020-05-06 Celgene Corporation METHODS OF TREATING VITILIGO WITH PD-1 BINDING PROTEINS
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
WO2018116267A2 (en) 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
JP7139332B2 (ja) 2016-12-23 2022-09-20 ノバルティス アーゲー 第ｘｉ因子抗体および使用方法
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
CN111107868A (zh) 2017-05-24 2020-05-05 诺华股份有限公司 抗体细胞因子移植蛋白及使用方法
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
MX2019014023A (es) 2017-05-24 2020-02-17 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer.
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
US11707522B2 (en) 2017-10-13 2023-07-25 Boehringer Ingelheim International Gmbh Human antibodies to Tn antigen
US20210040205A1 (en) 2017-10-25 2021-02-11 Novartis Ag Antibodies targeting cd32b and methods of use thereof
CN112004558A (zh) 2018-04-12 2020-11-27 米迪亚制药有限责任公司 Lgals3bp抗体-药物-偶联物及其用于癌症的治疗的用途
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
US20210139585A1 (en) 2019-05-21 2021-05-13 Novartis Ag Cd19 binding molecules and uses thereof
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021053559A1 (en) 2019-09-18 2021-03-25 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
JP2023523794A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 人工操作免疫グロブリン
WO2021220218A1 (en) 2020-05-01 2021-11-04 Novartis Ag Immunoglobulin variants
JP2023548529A (ja) 2020-11-06 2023-11-17 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
EP4271482A2 (en) 2020-12-31 2023-11-08 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
EP4362977A1 (en) 2021-06-29 2024-05-08 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
AR128222A1 (es) 2022-01-07 2024-04-10 Johnson & Johnson Entpr Innovation Inc MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) * 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
KR900005995A (ko) * 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
ES2251009T3 (es) * 1990-06-28 2006-04-16 Sanofi-Aventis Deutschland Gmbh Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso.
DE4137333A1 (de) * 1991-11-13 1993-05-19 W Prof Dr Sebald Therapeutische mittel, die antagonisten oder partielle agonisten des humanen interleukin 4 sind oder diese enthalten, hil-4-mutantenproteine sowie vefahren zu deren herstellung

Also Published As

Publication number Publication date
NO970374D0 (no) 1997-01-28
CN1164872A (zh) 1997-11-12
CZ25697A3 (en) 1997-09-17
CA2196200A1 (en) 1996-02-15
JPH10503371A (ja) 1998-03-31
AU3382595A (en) 1996-03-04
CN1117155C (zh) 2003-08-06
HUT76369A (en) 1997-08-28
EP0770135A1 (en) 1997-05-02
MX9700764A (es) 1997-05-31
BR9508469A (pt) 1997-09-16
NZ292124A (en) 1998-10-28
PL182665B1 (pl) 2002-02-28
WO1996004388A1 (en) 1996-02-15
PL318380A1 (en) 1997-06-09

Similar Documents

Publication Publication Date Title
NO970374D0 (no) Nye forbindelser
NO973231D0 (no) Nye forbindelser
NO960472L (no) Nye forbindelser
NO20000312L (no) Nye forbindelser
NO974646L (no) Nye forbindelser
NO20002787D0 (no) Nye forbindelser
FI955927A0 (fi) Substituoidut 1H-imidatsolit
NO970512D0 (no) Nye heteroaryl-oksazolidinoner
NO20001938D0 (no) Nye aryloksy-alkyl-dialkylaminer
NO983356D0 (no) Nye 19-nor-pregnenderivater
DE69534718D1 (de) Substituierte 9-alkyladenine
DK0906288T3 (da) Nye forbindelser
FI942119A0 (fi) Anordning i en gasblandare
DK0770132T3 (da) Nye streptograminer
NO960268D0 (no) Nye dialkoksypyridinylbenzimidazolderivater
NO990072D0 (no) Nye forbindelser
BR9509559A (pt) Azolilulsolfonilfeniluracilas substituídas
NO940195L (no) Nye forbindelser
NO991097D0 (no) Nye fremgangsmÕter
FI1516U1 (fi) Foerpackning foer i stapel anordnade smaoark
NO983505D0 (no) Nye fenantrider
DE59510274D1 (de) Substituierte biphenyloxazoline
FI1570U1 (fi) Instaellbart vinkelstycke foer central dammsugare
BR7401569U (pt) Central eletro-eletrônica
FI1839U1 (fi) Larmapparat foer fast montering i en byggnad

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application